On December 23, 2019, the FDA approved ubrogepant for the acute treatment of migraine with and without aura in adult patients.
Rimegepant (Nurtec ODT, Biohaven),a fast-acting orally disintegrating tablet, delivers quick and sustained efficacy for patients with migraine.
Eptinezumab-jjmr (Vyepti, Lundbeck) decreased mean monthly migraine days in adult patients in 2 phase 3 clinical trials.
Eli Lilly’s lasmiditan (Reyvow) C-V 50 mg and 100 mg for the acute treatment of migraine is now available for prescription.
Ubrogepant (Ubrelvy) is the first oral calcitonin gene-related peptide receptor antagonist approved by the FDA for the acute treatment of migraine.
Currently under DEA review.